<DOC>
	<DOCNO>NCT01836471</DOCNO>
	<brief_summary>The purpose study assess clinical effect QAW039 non-atopic asthmatic take low dose Inhaled Corticosteroid ( ICS ) background therapy .</brief_summary>
	<brief_title>A Study Assess Effect QAW039 Non-atopic Asthmatic Patients</brief_title>
	<detailed_description>This multi-centre , randomised , placebo-controlled , double blind , 3-arm study design compare efficacy safety daily dose QAW039 placebo non-atopic atopic asthmatic inadequately control despite receive low dose ICS background therapy , 12 week treatment period . Efficacy safety daily dose QAW039 also compare increase dose ICS atopic asthmatic take low dose ICS background therapy .</detailed_description>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Written informed consent must obtain assessment perform Patients diagnosis persistent asthma ( accord Global Initiative Asthma 2011 ) period least 6 month prior screen Patients prebronchodilator Forced Expiratory Volume In One Second ( FEV1 ) value 40 % 80 % individual predict value screen prior treatment An Asthma Control Questionnaire score â‰¥ 1.5 prior treatment Demonstration reversible airway obstruction Pregnant nursing ( lactate ) woman Acute illness asthma start study Patients clinically significant laboratory abnormality screen Patients clinically significant condition may compromise subject safety interfere study evaluation Use investigational drug time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>